Compare AbCellera Biologics Inc (ABCL) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares MSCI Indonesia ETF — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.85B), while iShares MSCI Indonesia ETF trades at $12.47. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | EIDO | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | — |
52-Week High | $9.34 | $19.22 |
52-Week Low | $2.78 | $10.80 |
Enterprise Value | $2.45B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
EIDO, the iShares MSCI Indonesia ETF, trades at $12.91, up 2.38% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows support and resistance clustered around $13. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs and reforestation plans, while facing challenges from foreign capital outflows and central bank rate hikes to support the rupiah.
The outlook for EIDO is mixed, with low valuation offering potential upside, but weak price action and high financial sector exposure limit gains. Risks include geopolitical volatility and dependence on commodity markets, though government reforms could boost long-term growth. Investors should weigh bargain valuations against macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
